TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9828759
Drug: 0 g/200
Normalized name: sodium polystyrene sulfonate 50 g/200 mL rectal enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/200 ml phytic acid (totally dephytinized soya milk)
Study: 9828759
Drug: 0.26 g/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.26 g/200 ml phytic acid (natural phytic acid content)
Study: 9828759
Drug: 0.13 g/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.13 g/200 ml phytic acid (half dephytinized soya milk)
Study: 8006401
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg every 6 h)
Study: 8006401
Drug: Vasopressin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin (0.4 to 0.8 unit per min) plus transdermal nitroglycerin (20 to 80 mg)
Study: 429083
Drug: Placebo (Elixophyllin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Elixophyllin Elixir, 250 mg)
Study: 429083
Drug: Isoproterenol inhalation
Normalized name: Isoproterenol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol inhalation
Study: 25919061
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg bid
Study: 17292948
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg bid
Study: 17292948
Drug: Rivaroxaban 30
Normalized name: rivaroxaban 30-Day Starter Pack (42-15 MG Oral Tablets & 9-20 MG Oral Tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 30 mg bid
Study: 17292948
Drug: Rivaroxaban 30
Normalized name: rivaroxaban 30-Day Starter Pack (42-15 MG Oral Tablets & 9-20 MG Oral Tablets)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 30 mg od
Study: 17292948
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg od
Study: 20062915
Drug: Rivaroxaban (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (all doses)
Study: 8299092
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care plus melatonin (20 mg/day at 8:00 p.m. orally)
Study: 8299092
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care alone (steroids plus anticonvulsant agents)
Study: 30578714
Drug: Treatment according
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment according to a protocol for precursor lymphoblastic lymphoma
Study: 1484577
Drug: EACA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EACA treatment before operation
Study: 1484577
Drug: No EACA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No EACA treatment
Study: 20947098
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone treatment during relapse
Study: 17186737
Drug: Basal hypoglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal hypoglycemic treatment (Control)
Study: 14617116
Drug: Atropine and
Normalized name: atropine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine and ketamine before propofol infusion
Study: 10709427
Drug: Intranasal nafarelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal nafarelin acetate (NA) 800 micrograms/d
Study: 10709427
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (LA) 0.5 mg/d
Study: 7019929
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg glucosamine sulphate (injectable)
Study: 7019929
Drug: Oral glucosamine
Normalized name: glucosamine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucosamine capsules (6 x 250 mg daily)
Study: 24754142
Drug: Placebo (oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral)
Study: 7019929
Drug: Piperazine/chlorbutanol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperazine/chlorbutanol combination (intravenous or intramuscular)
Study: 19680634
Drug: MDMA (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1.5 mg/kg)
Study: 19680634
Drug: MDMA (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (0.75 mg/kg)
Study: 24694926
Drug: MDMA (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (0.75 mg/kg) and MDMA (1.5 mg/kg)
Study: 19686592
Drug: TetraVisc 0.5%
Normalized name: TetraVisc 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: TetraVisc 0.5% (0.5 ml)
Study: 12511360
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% gel (1 ml)
Study: 10210927
Drug: Octreotide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (500 micrograms two times a day subcutaneous for six months)
Study: 7037043
Drug: 1 litre
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 litre of 0.9% sodium chloride solution intravenously over 1 h
Study: 7037043
Drug: No supplementary
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplementary infusion
Study: 30852882
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM)
Study: 27246602
Drug: Anthelmintic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthelmintic treatment
Study: 18703567
Drug: L-arginine/GHRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine/GHRH
Study: 18073313
Drug: L-arginine/GHRP-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine/GHRP-2
Study: 17066505
Drug: Phentermine-HCl 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine-HCl 37.5 mg once daily with behavioral therapy
Study: 17066505
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily with behavioral therapy
Study: 10853298
Drug: FA-specific IgE
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FA-specific IgE antibody measurement
Study: 8704111
Drug: Baseline active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline active kallikrein excretion
Study: 1793331
Drug: Perindopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (2 or 4 mg)
Study: 6133000
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g SASP daily
Study: 6133000
Drug: 1, 2,
Normalized name: Pneumococcal 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, 2, or 4 g SASP daily for 6 months
Study: 6133000
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg prednisolone daily for one week
Study: 6133000
Drug: Dummy tablets
Normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy tablets for one week
Study: 26837684
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy (n=47)
Study: 30625462
Drug: Dexlansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexlansoprazole 60 mg
Study: 17621520
Drug: Potassium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium bromide (started at 45 mg/kg, raised to 70 mg/kg)
Study: 15981008
Drug: Nadroparin (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (0.3 ml, 7,500 anti-Xa units)
Study: 12560610
Drug: Treatment strategy
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment strategy according to American College of Cardiology / American Heart Association practice guidelines (2002)
Study: 8742865
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (4 x 70 mg.kg‐1 body mass per day mixed with 5 g glucose)
Study: 8742865
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 x 10 g glucose per day)
Study: 2506503
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (NTG) at 0.25 micrograms/kg/min
Study: 2506503
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin (NTG) at 0.50 micrograms/kg/min
Study: 1112210
Drug: Three drugs
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three drugs (cyclophosphamide, methotrexate, and prednisone) given to 49 patients
Study: 707353
Drug: Zn supplement
Normalized name: zinc bandage with supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zn supplement
Study: 28780466
Drug: Cisplatin 50
Normalized name: cisplatin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 50 mg/m2 (GC50)
Study: 26037199
Drug: Sinetrol® XPur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinetrol® XPur (900 mg daily for 12 weeks)
Study: 25300286
Drug: Oral medication
Normalized name: Oral Medication Syringe 3mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication
Study: 12639582
Drug: Pre-treatment preference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment preference for hysterectomy
Study: 12639582
Drug: Pre-treatment preference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment preference for conservative option
Study: 12639582
Drug: Factors influencing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors influencing treatment choice
Study: 1283590
Drug: captopril 25mg
Normalized name: CAPTOPRIL 25MG TAB
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: captopril 25mg twice daily
Study: 3571940
Drug: Methylamphetamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylamphetamine (15 mg, intravenous)
Study: 3571940
Drug: Control (sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (sterile water, intravenous)
Study: 18758971
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation pharmacotherapy
Study: 29364489
Drug: Hindlimb suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hindlimb suspension (HS) for 2 weeks
Study: 8393389
Drug: Lisinopril therapy
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril therapy
Study: 11106716
Drug: 180 microg
Normalized name: Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 microg of peginterferon alfa‐2a once weekly
Study: 11106716
Drug: 90 microg
Normalized name: Linaclotide 290 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 microg of peginterferon alfa‐2a once weekly
Study: 11106716
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units of interferon alfa‐2a three times weekly
Study: 9053508
Drug: Monthly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly regimen of IV LV 20 mg/m2 plus bolus 5‐FU 425 mg/m2 for 5 days every 4 weeks
Study: 9053508
Drug: Bimonthly regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimonthly regimen of IV LV 200 mg/m2 as a 2-hour infusion followed by bolus 5‐FU 400 mg/m2 and 22-hour infusion 5‐FU 600 mg/m2 for 2 consecutive days every 2 weeks
Study: 8372720
Drug: Bucillamine (Bu)
Normalized name: bucillamine
DrugBank: Bucillamine (DB12160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucillamine (Bu) 3200 mg (single administration)
Study: 29565771
Drug: α1-receptor blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: α1-receptor blockade via oral prazosin (0.05 mg/kg body wt)
Study: 22192944
Drug: Monthly visits
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly visits by Community Health Workers (CHWs)
Study: 17371478
Drug: Meal B
Normalized name: ameal bp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal B (220 kcal, 5 g lipid)
Study: 17371478
Drug: Meal C
Normalized name: Wholemeal chapati
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal C (474 kcal, 19 g lipid)
Study: 17371478
Drug: Meal D
Normalized name: Dimethicone 13 mg in 1 g TOPICAL LOTION [Oatmeal Daily Moisturizing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meal D (837 kcal, 44 g lipid)
Study: 10666525
Drug: General practitioner
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practitioner treatment (GP-group), n=63
Study: 3730264
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose salbutamol treatment
Study: 20205227
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (in subgroup without epidural blockade or laparoscopic surgery)
Study: 20205227
Drug: Preoperative carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative carbohydrate (CHO) treatment
Study: 31867651
Drug: Gradual nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual nicotine reduction to 0.04 mg nicotine/g of tobacco
Study: 14766715
Drug: Dextrose concentrations
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose concentrations (10, 20, 30, 50, and 80 g ml(‐1)) added to 5 g ml(‐1) solutions
Study: 9024172
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg valsartan
Study: 9290986
Drug: Sucralfate administration
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate administration
Study: 21420555
Drug: NASHA Dx
Normalized name: brompheniramine maleate / dextromethorphan hydrobromide / pseudoephedrine hydrochloride Oral Solution [Myphetane DX]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NASHA Dx (transanal submucosal injections)
Study: 8590556
Drug: Control situation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control situation (no treatment)
Study: 1098705
Drug: Synthetic anticholinergic
Normalized name: Synthetic anticholinergics, quaternary ammonium compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic anticholinergic drug (SCH 10000)
Study: 31742366
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity laser therapy (HILT) with a power of 1.6 W and low fluence of 8 J/cm2
Study: 31282081
Drug: 14-day therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day therapy with levofloxacin (750 mg), clarithromycin-MR (1 g), rabeprazole (60 mg), and bismuth subsalicylate (1,048 mg)
Study: 31282081
Drug: 7-day therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day therapy with levofloxacin (750 mg), clarithromycin-MR (1 g), rabeprazole (60 mg), and bismuth subsalicylate (1,048 mg)
Study: 19841844
Drug: Function-centred inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Function-centred inpatient treatment
Study: 9516063
Drug: Galanin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galanin infusion (8 microg/Kg/h) in healthy volunteers (group I)
Study: 9516063
Drug: Galanin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galanin infusion (8 microg/Kg/h) in cured acromegaly patients (group III)
Study: 8034992
Drug: Dirithromycin, 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin, 500 mg once daily
Study: 8034992
Drug: Erythromycin, 250
Normalized name: Erythromycin, 250 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin, 250 mg four times daily
Study: 6419263
Drug: Plasma haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma haloperidol levels (4.2‐11.0 ng/ml) during the first 14 days of treatment
Study: 23176984
Drug: Intrathecal 4
Normalized name: LIORESAL INTRATHECAL 40 MG in 20 ML (2,000 MCG/ML) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 4 mg bupivacaine 0.5% + 25 μg fentanyl
Study: 21214129
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 1.2%-benzoyl peroxide 2.5% gel
Study: 9778066
Drug: Ibutilide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (1 mg)
Study: 16351670
Drug: Propafenone (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (70 mg)
Study: 12361104
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL ipecac syrup
Study: 27600897
Drug: Prolatan (latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolatan (latanoprost 0.005%) once daily in the evening
Study: 27600897
Drug: Xalatan (latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xalatan (latanoprost 0.005%) once daily in the evening
Study: 20032239
Drug: Platform dropped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform dropped (8 cm, 0.9 g acceleration)
Study: 18534330
Drug: Swedish-style massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swedish-style massage therapy
Study: 25240453
Drug: Rosuvastatin 40
Normalized name: rosuvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 40 mg
Study: 15215813
Drug: Rosuvastatin 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 80 mg
Study: 14512129
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 to 80 mg)
Study: 9308064
Drug: Acetaminophen 15
Normalized name: acetaminophen 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 15 mg.kg‐1
Study: 3522770
Drug: Single initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single initial 1500 mg dose of rifampin plus daily doses of 100 mg of dapsone
Study: 27160957
Drug: l-Citrulline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Citrulline (6 g/d) for 14 d
Study: 12171842
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg daily oral corticosteroids
Study: 10404930
Drug: Gradual withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual withdrawal of psychotropic medication
Study: 10404930
Drug: Continuing to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing to take psychotropic medication
Study: 31053134
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of daily OCS dose by 5 mg/day
Study: 22293680
Drug: Low-dose caffeine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose caffeine (200 mg total from 2 pieces of chewing gum) administered at 3 different time points (‐35, ‐5, and +15 minutes) during cycling exercise
Study: 22293680
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at the other 2 points and at all 3 points in the control trial
Study: 20216490
Drug: Ultrasound irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound irradiation administered to the pressure ulcer through the same dressing used in standard treatment (pulsed ultrasound, 20% duty cycle, 0.5W/cm2, 1MHz or 3MHz, for 10 minutes, five times weekly)
Study: 15767639
Drug: Warfarin 1
Normalized name: warfarin 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin 1 mg daily
Study: 9822184
Drug: Esmolol (ultra-short
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (ultra-short acting beta-blocker)
Study: 6958476
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and beta 2-adrenergic agonist terbutaline (Group 2)
Study: 6958476
Drug: Beta 2-adrenergic
Normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2-adrenergic agonist alone (additional group of 7 patients)
Study: 20069077
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg/day plus aspirin 81 mg/day
Study: 20069077
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin 81 mg/day
Study: 12512888
Drug: Customary oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customary oral hygiene
Study: 12512888
Drug: Neglected oral
Normalized name: Malva neglecta whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neglected oral hygiene
Study: 27798032
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy
Study: 24284437
Drug: Isoleucine (5‐216
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoleucine (5‐216 mg · kg(‐1) · d(‐1))
Study: 24284437
Drug: Leucine (5‐370
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucine (5‐370 mg · kg(‐1) · d(‐1))
Study: 24284437
Drug: Valine (5‐236
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valine (5‐236 mg · kg(‐1) · d(‐1))
Study: 22929451
Drug: 1 drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop of cyclopentolate 0.2% and phenylephrine 1% ophthalmic solution
Study: 22929451
Drug: 3 drops
Normalized name: UpSpring WellBaby DHA + Vitamin D3 Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 drops of cyclopentolate 0.2% and phenylephrine 1% ophthalmic solution (treatment reference group)
Study: 22929451
Drug: 0 drops
Normalized name: MENTHOL 2.7 mg ORAL SUSPENSION/ DROPS [FREEGELLS COUGH DROPS MENTHOL STRAWBERRY 30 DROPS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 drops of cyclopentolate 0.2% and phenylephrine 1% ophthalmic solution (control group)
Study: 18579668
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate 3000 mg/d
Study: 18579668
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate 3750 mg/d
Study: 18579668
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lanthanum carbonate 4500 mg/d
Study: 7450412
Drug: Oral 16,16-dimethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 16,16-dimethyl PGE2 at 1 microgram/kg
Study: 7450412
Drug: Intravenous 16,16-dimethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 16,16-dimethyl PGE2 at 0.1 microgram/kg